Literature DB >> 20437868

Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.

Araceli Cánovas1, Juan J Alonso, Guillermo Barreiro, Ciriaco Aguirre.   

Abstract

AIMS AND
BACKGROUND: The Follicular Lymphoma International Prognostic Index (FLIPI) is a useful tool for the prognostic assessment of follicular lymphoma but beta-2 microglobulin (B2M) was not incorporated in this index. We aimed to compare the predictive value of B2M, FLIPI and other prognostic factors not included in the FLIPI index for overall survival (OS), complete remission (CR), and time to treatment failure (TTF) in a nonselected follicular lymphoma series. METHODS AND STUDY
DESIGN: Retrospective univariate and multivariate analysis of the prognostic value (for OS, CR, TTF) of B2M, FLIPI and other prognostic variables in follicular lymphoma was conducted in a cohort of follicular lymphoma patients between 1987 and 2007.
RESULTS: One hundred and six patients were studied. In univariate analysis B2M and B symptoms were significantly associated with OS, and FLIPI only detected two risk levels. In multivariate analysis of OS only two significant variables were found: FLIPI and B2M. Multivariate analysis of CR showed that normal B2M, absence of a bulky mass, uninvolved bone marrow, and chemotherapy with rituximab were significant predictors of CR. FLIPI (three levels), B2M, bone marrow infiltration, and chemotherapy with rituximab were significantly associated with TTF.
CONCLUSIONS: We found a high predictive value of B2M for OS, CR, and TTF. B2M and FLIPI were the most important variables to predict OS. However, in our series FLIPI differentiated only between two mortality risk levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437868     DOI: 10.1177/030089161009600119

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  6 in total

1.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

2.  Novel prognostic scoring system for diffuse large B-cell lymphoma.

Authors:  Pan Zhao; Li Zang; Xiaoying Zhang; Yafang Chen; Zhijie Yue; Hongliang Yang; Haifeng Zhao; Yong Yu; Yafei Wang; Zhigang Zhao; Yizhuo Zhang; Xiaofang Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

3.  Expression kinetics of chicken β2-microglobulin and Class I MHC in vitro and in vivo during Marek's disease viral infections.

Authors:  Chuan Yu; Qiu Liu; Aijian Qin; Xuming Hu; Wencai Xu; Kun Qian; Hongxia Shao; Wenjie Jin
Journal:  Vet Res Commun       Date:  2013-08-06       Impact factor: 2.459

4.  A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Authors:  Oliver W Press; Joseph M Unger; Lisa M Rimsza; Jonathan W Friedberg; Michael LeBlanc; Myron S Czuczman; Mark Kaminski; Rita M Braziel; Catherine Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker R Dakhil; Thomas P Miller; Richard I Fisher
Journal:  Clin Cancer Res       Date:  2013-10-15       Impact factor: 12.531

5.  Primary Gastric Diffuse Large B-Cell Lymphoma: Prognostic Factors in the Immuno-Oncology Therapeutics Era

Authors:  ZhiMin Bai; ZhenHua Li; Tao Guan; LieYang Wang; JingRong Wang; ShaoHua Wu; LiPing Su
Journal:  Turk J Haematol       Date:  2020-03-12       Impact factor: 1.831

6.  Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach.

Authors:  Piyanoot Fonghem; Trairak Pisitkun; Kasem Rattanapinyopituk; Sirintra Sirivisoot; Anudep Rungsipipat
Journal:  Vet World       Date:  2022-05-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.